Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Dranitsaris

Showing results (41-50 of 50) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 50 results.
Breast Cancer Research and Treatment|September 5, 2009
A randomized trial exploring the biomarker effects of neoadjuvant sequential treatment with exemestane and anastrozole in post-menopausal women with hormone receptor-positive breast cancerO C Freedman, E Amir, W Hanna, et al.
Breast Cancer Research and Treatment|October 17, 2013
Preference weights for chemotherapy side effects from the perspective of women with breast cancerI Kuchuk, N Bouganim, K Beusterien, et al.
Current Oncology (Toronto, Ont.)|June 20, 2007
Prevention and management of chemotherapy-induced diarrhea in patients with colorectal cancer: a consensus statement by the Canadian Working Group on Chemotherapy-Induced DiarrheaJ A Maroun, L B Anthony, N Blais, et al.
Pharmacoeconomics|April 7, 1998
Economic analysis of fluconazole versus amphotericin B for the treatment of candidemia in non-neutropenic patientsG Dranitsaris, P Phillips, C Rotstein, et al.
Clinicoeconomics and Outcomes Research : CEOR|March 23, 2018
Modeling the economic outcomes of immuno-oncology drugs: alternative model frameworks to capture clinical outcomesE J Gibson, N Begum, I Koblbauer, et al.
Breast Cancer Research and Treatment|December 9, 2015
A randomized, double-blind, phase II, exploratory trial evaluating the palliative benefit of either continuing pamidronate or switching to zoledronic acid in patients with high-risk bone metastases from breast cancerC Jacobs, I Kuchuk, N Bouganim, et al.
Bone Marrow Transplantation|January 23, 1999
Clinical and economic analysis of allogeneic peripheral blood progenitor cell transplants: a Canadian perspectiveS Couban, G Dranitsaris, P Andreou, et al.
Urologic Oncology|June 24, 2021
An economic analysis comparing health care resource use and cost of dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin versus gemcitabine and cisplatin as neoadjuvant therapy for muscle invasive bladder cancerK Montazeri, G Dranitsaris, J D Thomas, et al.
Breast (Edinburgh, Scotland)|November 26, 2020
A randomized trial of individualized versus standard of care antiemetic therapy for breast cancer patients at high risk for chemotherapy-induced nausea and vomitingM Clemons, G Dranitsaris, M Sienkiewicz, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 19, 2025
Personalised antiemetic prophylaxis with NEPA for patients at high risk of chemotherapy-induced nausea and vomiting receiving moderately emetogenic chemotherapy: results from the randomised, multinational MyRisk trialA Molassiotis, K Jordan, M Karthaus, et al.
Pageof 5

Showing results (41-50 of 50) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 50 results.
Breast Cancer Research and Treatment|September 5, 2009
A randomized trial exploring the biomarker effects of neoadjuvant sequential treatment with exemestane and anastrozole in post-menopausal women with hormone receptor-positive breast cancerO C Freedman, E Amir, W Hanna, et al.
Breast Cancer Research and Treatment|October 17, 2013
Preference weights for chemotherapy side effects from the perspective of women with breast cancerI Kuchuk, N Bouganim, K Beusterien, et al.
Current Oncology (Toronto, Ont.)|June 20, 2007
Prevention and management of chemotherapy-induced diarrhea in patients with colorectal cancer: a consensus statement by the Canadian Working Group on Chemotherapy-Induced DiarrheaJ A Maroun, L B Anthony, N Blais, et al.
Pharmacoeconomics|April 7, 1998
Economic analysis of fluconazole versus amphotericin B for the treatment of candidemia in non-neutropenic patientsG Dranitsaris, P Phillips, C Rotstein, et al.
Clinicoeconomics and Outcomes Research : CEOR|March 23, 2018
Modeling the economic outcomes of immuno-oncology drugs: alternative model frameworks to capture clinical outcomesE J Gibson, N Begum, I Koblbauer, et al.
Breast Cancer Research and Treatment|December 9, 2015
A randomized, double-blind, phase II, exploratory trial evaluating the palliative benefit of either continuing pamidronate or switching to zoledronic acid in patients with high-risk bone metastases from breast cancerC Jacobs, I Kuchuk, N Bouganim, et al.
Bone Marrow Transplantation|January 23, 1999
Clinical and economic analysis of allogeneic peripheral blood progenitor cell transplants: a Canadian perspectiveS Couban, G Dranitsaris, P Andreou, et al.
Urologic Oncology|June 24, 2021
An economic analysis comparing health care resource use and cost of dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin versus gemcitabine and cisplatin as neoadjuvant therapy for muscle invasive bladder cancerK Montazeri, G Dranitsaris, J D Thomas, et al.
Breast (Edinburgh, Scotland)|November 26, 2020
A randomized trial of individualized versus standard of care antiemetic therapy for breast cancer patients at high risk for chemotherapy-induced nausea and vomitingM Clemons, G Dranitsaris, M Sienkiewicz, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 19, 2025
Personalised antiemetic prophylaxis with NEPA for patients at high risk of chemotherapy-induced nausea and vomiting receiving moderately emetogenic chemotherapy: results from the randomised, multinational MyRisk trialA Molassiotis, K Jordan, M Karthaus, et al.
Pageof 5